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Mutations in SLC39A14 disrupt manganese
homeostasis and cause childhood-onset
parkinsonism–dystonia
Karin Tuschl et al.#
Although manganese is an essential trace metal, little is known about its transport and
homeostatic regulation. Here we have identiﬁed a cohort of patients with a novel autosomal
recessive manganese transporter defect caused by mutations in SLC39A14. Excessive
accumulation of manganese in these patients results in rapidly progressive childhood-onset
parkinsonism–dystonia with distinctive brain magnetic resonance imaging appearances and
neurodegenerative features on post-mortem examination. We show that mutations in
SLC39A14 impair manganese transport in vitro and lead to manganese dyshomeostasis and
altered locomotor activity in zebraﬁsh with CRISPR-induced slc39a14 null mutations.
Chelation with disodium calcium edetate lowers blood manganese levels in patients and can
lead to striking clinical improvement. Our results demonstrate that SLC39A14 functions as a
pivotal manganese transporter in vertebrates.
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P
recise physiological homeostasis of the essential trace metal
manganese (Mn) is crucial for normal cell function. Mn
acts as a cofactor for multiple enzymes and is involved in
numerous physiological processes, including some that are critical
for neuronal and glial cell function, such as neurotransmitter
synthesis1,2.
Due to the ubiquity of Mn, nutritional deﬁciency of this trace
metal has rarely been observed3. However, mutations in
SLC39A8, encoding a Mn uptake transporter, have recently
been recognized to cause a severe Mn depletion syndrome
associated with developmental delay, cerebellar atrophy, epilepsy
and short stature4,5. Biochemically, this disorder is accompanied
by dysglycosylation resembling a type II congenital disorder of
glycosylation (CDG) due to dysfunction of Mn-dependent
enzymes such as the beta 1, 4 glycosyltransferase involved in
galactosylation of glycoproteins4.
Excessive Mn concentrations on the other hand are neurotoxic
and lead to manganism—a parkinsonian movement disorder
caused by accumulation of Mn in the basal ganglia6. When
the homeostatic mechanisms of the gut, which regulates gastro-
intestinal Mn absorption, and/or the liver, which modulates the
biliary excretion of Mn, fail, get bypassed or are overwhelmed,
rising Mn blood levels subsequently result in Mn deposition in
the brain6,7. Mn overexposure can occur in welding and mining
industries, in individuals using Mn contaminated Ephedrone
preparations, and in patients receiving high Mn concentrations in
total parenteral nutrition8–10. Impaired hepatic Mn excretion
in chronic liver disease may cause ‘acquired hepatocerebral
degeneration’11. Mn toxicity also plays a role in the pathogenesis
of other neurodegenerative disorders such as Parkinson’s disease
(PD)1,12. Several early-onset parkinsonism genes including
PARK2 (Parkin) and PARK9 (ATP13A2) are associated with
Mn dyshomeostasis. Affected patients share common neuro-
pathological features of Mn neurotoxicity, including oxidative
stress and mitochondrial dysfunction, impaired autophagy and
altered alpha-synuclein aggregation1,12. Indeed, Parkin and
ATP13A2 are postulated to protect dopaminergic cells from Mn
toxicity13–15. Furthermore, polymorphisms in ATP13A2 are
associated with increased susceptibility to Mn toxicity16. Alpha-
synuclein is also suggested to act as an intracellular Mn store17,
and Mn exposure promotes alpha-synuclein oligomerization and
enhances cellular toxicity18–20.
Recently, mutations in SLC30A10 have been found to cause an
inherited disorder of Mn metabolism21,22. SLC30A10 encodes a
divalent cation transporter expressed on the cell membrane in
liver and brain where it mediates efﬂux of Mn23. In affected
individuals, Mn accumulates in the basal ganglia and the liver
causing parkinsonism–dystonia, chronic liver disease, hyper-
manganesemia, polycythaemia and abnormal iron indices21,22.
Polymorphisms in SLC30A10 are associated with increased blood
Mn levels and impaired neurological function affecting sway
velocity and ﬁnger-tapping speed24,25.
Although the importance of Mn in multiple disease processes is
increasingly recognized, transport and homeostatic regulation of
Mn in vivo are poorly understood. Several transporters have been
postulated to play a role in Mn homeostasis and regulation,
however, it remains unknown which of these are
crucial4,5,14,23,26–34.
In this study, we have identiﬁed a cohort of children with
hypermanganesemia and progressive parkinsonism–dystonia who
carry homozygous loss-of-function mutations in SLC39A14.
We show that disodium calcium edetate (Na2CaEDTA)
effectively chelates Mn and increases urinary Mn excretion in
affected individuals. Commenced early in the disease course,
chelation therapy can lead to signiﬁcant improvement of clinical
symptoms and, potentially, prevention of disease progression.
Our results also demonstrate that SLC39A14 functions as
a primary Mn transporter and that mutations in SLC39A14
impair Mn uptake, without affecting zinc (Zn), iron (Fe) and
cadmium (Cd) blood levels. This is further corroborated in
zebraﬁsh carrying CRISPR-induced mutations in the slc39a14
orthologue which also show Mn dyshomeostasis while other
metals remain unaffected. Our ﬁndings bring new insights into
Mn transport and provide a novel zebraﬁsh disease model in
which to elucidate the mechanisms underlying Mn-related
disease.
Results
SLC39A14 mutations cause Mn-associated neurodegeneration.
SLC39A14 is a divalent metal transporter, also known as Zrt,
Irt-like protein 14 (ZIP14), that belongs to the LIV-1 subfamily
whose members contain eight transmembrane domains (TMDs),
a histidine-rich motif (HXHXHX), and a metalloprotease motif
(H/EEXPHEXGD) required for metal transport35,36 (Fig. 1a).
While most SLC39 transporters are speciﬁc for Zn there is
evidence that SLC39A14 also transports Mn, Fe and Cd31,37,38.
Using whole-exome sequencing (WES), in conjunction with
autozygosity mapping and Sanger sequencing, we identiﬁed
homozygous changes in the coding region of SLC39A14 in eight
patients from ﬁve unrelated consanguineous families presenting
with hypermanganesemia and progressive movement disorder
(Table 1, Fig. 1b, Supplementary Fig. 1). The identiﬁed mutations
include three missense changes (F98V, G383R, N469K) that affect
highly conserved amino-acid residues, as well as a nonsense
(E105X) and frame-shift mutations (S160Cfs*5) that are expected
to generate signiﬁcantly truncated proteins (Fig. 1a, Supple-
mentary Fig. 2). The G383R mutation is located within the
EEXPHEXGD motif required for metal binding35. Although it
affects the last nucleotide of exon 7 (c.1147G4A), splicing is
unaffected (Supplementary Fig. 3). Human SLC39A14 encodes
three isoforms due to alternative splicing of exon 4 and 9
(Supplementary Fig. 4) (ref. 32). The S160Cfs*5 mutation is
caused by a 2-bp deletion within exon 4A, solely affecting isoform
2. The clinical phenotype of this individual was not signiﬁcantly
different to that of the remaining patient cohort. Mendelian
segregation of the mutations within the family was veriﬁed for
cases where parent DNA was available (Fig. 1b). None of the
identiﬁed sequence changes have been reported previously
including the dbSNP, 1,000 Genomes Project and ExAC
databases (see URLs). Recessive variants in 15 genes causing
early-onset PD or Mn dyshomeostasis (Supplementary Table 1)
were excluded by analysing the WES data for subject B-II-4,
D-II-1 and E-II-4.
Patients with SLC39A14 mutations showed common clinical
features and disease course (Supplementary Note 1,
Supplementary Movies 1, 3–5). Affected children presented with
loss of developmental milestones, progressive dystonia and bulbar
dysfunction in infancy or early childhood. Towards the end of the
ﬁrst decade, they developed severe generalized pharmacoresistant
dystonia, spasticity, limb contractures and scoliosis, and lost
independent ambulation. Some showed parkinsonian features of
hypomimia, tremor and bradykinesia. There appeared to be a
degree of cognitive sparing relative to the motor disability. Three
children died between 13 months and 7 years, two due to
respiratory infections and for the third the cause of death is
unknown.
Magnetic resonance imaging (MRI) brain features were
characteristic of Mn deposition (Fig. 1c, Supplementary
Table 2). Within the deep grey matter, T1-weighted hyperinten-
sity was present in the globus pallidus and, to a lesser extent, the
striatum, with thalamic sparing. Generalized T1-hyperintensity
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indicated extensive white matter involvement including the
cerebellum, spinal cord and dorsal pons, with sparing of the
ventral pons. Sagittal T1-weighted sequences demonstrated
hyperintense signal of the anterior pituitary gland. Axial
T2-weighted imaging (T2, T2* and FLAIR sequences) showed
hypointensity of the globus pallidus which was progressive in one
patient (Supplementary Fig. 5a). Some patients had evidence of
cerebral and cerebellar atrophy (Supplementary Fig. 5b,c).
Computed tomography imaging undertaken in one patient was
normal (Supplementary Fig. 5d).
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In all tested patients, whole-blood Mn levels were markedly
elevated relative to the reference range (Table 1). Blood levels of
Fe, Zn and Cd, divalent metals that can be transported by
SLC39A14 in in vitro assays37,39, were assessed in two patients
using inductively coupled plasma–mass spectrometry (ICP-MS)
and found to be normal when compared with control subjects
and literature reference ranges (Table 2) (refs 40,41). Mn levels
were normal in heterozygous parents.
In contrast to SLC30A10 deﬁciency21,22, children with
SLC39A14 mutations did not develop polycythaemia or liver
disease. Liver MRI of individual E-II-4 showed no obvious
increase in T1-weighted signal intensity, suggesting that Mn does
not accumulate in the liver in this disorder (Fig. 2a). Iron indices
including total iron-binding capacity and ferritin were normal.
Unlike patients with Mn deﬁciency due to mutations in slc39a8
(ref. 4), glycosylation of transferrin, assessed in patient E-II-2, was
unaffected despite the Mn overload.
Post-mortem examination performed on individual D-II-1
who died of septic shock following a bronchopneumonia at 4
years of age revealed marked neuronal loss in the globus pallidus
(Fig. 2b) while neurons in the caudate, putamen, thalamus and
cerebral cortex were relatively well-preserved. Similar severe
neuronal loss and gliosis were observed in the dentate nucleus of
the cerebellum with relative preservation of the cerebellar cortex.
Patchy loss of myelin staining was evident in the cerebral and
cerebellar white matter associated with coarse vacuoles (some
over 50 mm) and patchy axonal loss on neuroﬁlament staining.
A few rounded eosinophilic spheroid structures were noted in the
dentate nucleus, but neuropathological features of iron deposition
(negative Perls’ stain), axonal spheroids, tau and alpha-synuclein
pathology were not observed.
Na2CaEDTA lowers blood Mn and alleviates clinical symptoms.
In an attempt to reduce the systemic Mn load, individuals C-II-2
and E-II-2 were commenced on chelation therapy with i.v.
Na2CaEDTA according to a protocol published for SLC30A10
deﬁciency42,43. Individual C-II-2, who was started early on in the
disease course at 5 years of age, tolerated chelation therapy well
without notable side effects and showed dramatic clinical
improvement. After 6 months of monthly Na2CaEDTA courses
(500mg twice daily for 5 consecutive days) upper limb tremors
and athetoid movements had ceased and lower limb dystonia
improved to the extent that she regained the ability to
walk independently with foot orthoses (Supplementary Movies
1 and 2).
For subject E-II-2, who was commenced on chelation at 17
years of age, Na2CaEDTA administration (20mg kg 1 per day)
led to marked increase in urinary Mn excretion accompanied by
reduction of blood Mn levels (Fig. 2c). Despite mobilization of
Mn stores she has continued to deteriorate with worsening
tremor and stiffness. Na2CaEDTA therefore appears to effectively
chelate Mn in this disorder; however, clinical response can be
variable, possibly due to patient age and disease severity at
treatment onset.
Tissue expression and Mn transport differ between isoforms.
Immunostaining of sections of human control liver showed that
SLC39A14 localized to the cell membrane and the cytoplasm of
hepatocytes in a punctate pattern (Fig. 3a). In the brain,
SLC39A14 was detected in large neurons, especially in the globus
pallidus, insular cortex and dentate nucleus, occasionally in the
putamen and rarely in the caudate nucleus (Fig. 3a,
Supplementary Fig. 6). Comparable subcellular localization was
seen when C-terminally eGFP-tagged human SLC39A14 was
expressed in zebraﬁsh embryos. Both isoforms 1 and 2 localize to
the cell membrane and the cytoplasm (Fig. 3b,c).
Given that individual C-II-2 carries mutations that only affect
isoform 2, tissue expression and function of both SLC39A14
isoform 1 and 2 were examined. The isoforms differ by 20 amino
acids encoded by exon 4A and 4B, respectively (Supplementary
Figs 4 and 7). Reverse transcription–PCR (RT–PCR) showed that
transcript 1 was ubiquitously expressed in all tissues examined
while transcript 2 was not detected in the brain (Fig. 3d).
Transient expression of wild-type SLC39A14 isoform 1 and 2 in
HEK-293 cells conﬁrmed that both facilitate Mn uptake (Fig. 3e).
However, isoform 2 showed a greater ability to transport Mn than
isoform 1. These results indicate that both isoforms localize to the
cell membrane where they facilitate Mn uptake, albeit potentially
with different efﬁcacy.
Mn affects transcriptional regulation of zebraﬁsh slc39a14. In
other contexts, expression of metal transporters is controlled by
the concentration of their substrate thereby ensuring tight
regulation of metal levels44–46. We assessed the effect of Mn on
expression of zebraﬁsh slc39a14 by quantitative PCR (qPCR).
Acute MnCl2 exposure (500 mM for 24 h) of zebraﬁsh larvae at 4
days post fertilization (dpf) led to a signiﬁcant increase in
slc39a14 expression. This increase in expression was caused by
upregulation of transcript 2 mRNA levels while levels of
transcript 1 remained unchanged (Fig. 3f). Transcriptional
regulation of slc39a14 by its substrate is therefore likely to
contribute to Mn homeostasis. Subchronic MnCl2 exposure
(50 mM, 72 h) on the other hand did not signiﬁcantly affect
slc39a14 transcript levels (data not shown).
Missense mutations in human SLC39A14 impair Mn uptake.
The impact of F98V, G383R and N469K variants on SLC39A14
protein localization and function was investigated in stably
transfected HEK-293 cells expressing N-terminal FLAG-tagged
wild-type and mutant SLC39A14. Immunoblotting studies
showed that overall expression of mutant SLC39A14 in total cell
lysates was similar to wild-type SLC39A14 (Fig. 4a,b,
Supplementary Fig. 8). Immunoﬂuorescence staining of non-
permeabilized (Fig. 4c) and permeabilized (Fig. 4d) HEK-293 cells
Figure 1 | SLC39A14 mutations lead to cerebral Mn deposition associated with characteristic MRI brain appearances. (a) Schematic of SLC39A14
showing its eight TMDs (pink and blue cylinders) interlinked by intracellular and extracellular loops35. TMD II, III, IV and VII (pink) are postulated by the
transmembrane protein topology prediction tool MemSatSVM (see URLs) to form a pore. The histidine-rich (HXHXHX) and metalloprotease motif
(EEXPHEXGD) are highlighted in orange. Mutated amino-acid residues are indicated by red circles. (b) Pedigrees and sequence chromatograms of family
A-E. Affected individuals are indicated by black shading. Squares represent males, circles females and a double line a consanguineous union. Mutated bases
are boxed in black. For each family, the top chromatogram shows the wild-type SLC39A14 sequence and the hromatogram below the homozygous
SLC39A14 mutation identiﬁed in the affected individuals. Parental studies for families A, B, C and E demonstrate that both parents are heterozygous carriers
of the identiﬁed mutation. (c) Representative MRI brain images of patients with SLC39A14 mutations showing characteristic radiological features: individual
C-II-2 aged 3 years and E-II-2 aged 17 years. Generalized T1-hyperintensity of the cerebral white matter, globus pallidus (yellow arrows) and striatum (blue
arrows), pituitary gland (white arrows), dorsal pons (pink arrows) and cerebellum (turquoise arrows) can be observed. Hypointensity of the globus pallidus
is also evident on T2 and T2*-weighted imaging (white dashed arrows).
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with anti-FLAG antibody conﬁrmed similar subcellular localiza-
tion patterns for both wild-type and mutant SLC39A14 at the cell
surface and within the cytosol. Investigation of mutant SLC39A14
transporter activity following MnCl2 exposure (1 mM; 15min)
showed reduced Mn levels for cells expressing mutant protein,
particularly mutants F98V and G383R, when compared with
those expressing wild-type protein (Fig. 4e).
slc39a14 loss-of-function causes Mn disturbance in zebraﬁsh.
To further elucidate the role of SLC39A14 in Mn homeostasis, we
generated a zebraﬁsh model of Slc39a14 deﬁciency by CRISPR/
Cas9 genome editing. RT–PCR conﬁrmed expression of zebraﬁsh
slc39a14 at all stages of embryonic and early larval development
(Fig. 5a). Whole-mount in situ hybridization demonstrated
slc39a14 expression in the proximal pronephric ducts at 4 dpf
(Fig. 5b, Supplementary Fig. 9). 50 and 30 RACE showed that
zebraﬁsh, as for human SLC39A14, have an alternative fourth and
ninth exon and, in addition, an alternative eighth exon encoding a
fourth splice isoform (Supplementary Fig. 10). Sequence
alignment of human and zebraﬁsh Slc39a14 demonstrated that
both proteins share high sequence homology. About 62% of
amino-acid residues are identical with a higher degree of
conservation observed around the TMDs and the metalloprotease
motif (Supplementary Fig. 11), suggesting that the human and
ﬁsh Slc39a14 transporters are likely to have comparable functions.
A zebraﬁsh mutant line that carries a slc39a14 null mutation
(slc39a14U801) in exon 5, which is shared by all transcripts, was
generated using CRISPR/Cas9 genome editing (Supplementary
Fig. 12) (refs 47,48). The mutant harbours a frame-shift mutation
P210Hfs*48 (c.629_630del) predicted to truncate the protein by
246 amino acids with loss of the metal-binding domain and TMD
III to VIII (Fig. 5c, Supplementary Fig. 11). Because an antibody
to zebraﬁsh Slc39a14 is not available, we assessed slc39a14 mRNA
expression in homozygous slc39a14U801 mutants and found it
markedly reduced (Fig. 5d), suggesting nonsense-mediated decay
of the mutant transcripts.
Homozygous slc39a14U801 mutants showed a 35% increase in
Mn levels at 5 dpf and 72% increase at 14 dpf, conﬁrming a
crucial role for Slc39a14 in Mn clearance (Fig. 6a).
Other previously reported substrates of the transporter, including
Fe, Zn and Cd37, were unaffected (Fig. 6b). Larval length did not
differ between mutant and wild-type larvae, excluding differences in
size accounting for the observed difference in Mn levels
Table 1 | Clinical characteristics and SLC39A14 mutations identiﬁed in affected patients.
Subject Gender Method used
to identify
mutation
SLC39A14
mutation*
Amino-acid
change
Exon Isoform Country
of origin
Age of
onset
Current age Whole-blood
Mn (73–325 nmol l 1)
A-II-1 F S c.[292T4G];
[292T4G]
p.[F98V];
[F98V]
3 1–3 Yemen 7
months
13 years 2,887
A-II-2 F S c.[292T4G];
[292T4G]
p.[F98V];
[F98V]
3 1–3 Yemen 6
months
w (7 years) NA
B-II-1 F z z z z z Egypt 7
months
w (13 months) NA
B-II-4 F WES/S c.[313G4T];
[313G4T]
p.[E105X],
[E105X]
3 1–3 Egypt 7
months
3 years 8,101
C-II-2 F S c.[477_478del];
[477_478del]
p.[S160Cfs*,5],
[S160Cfs*5]
4B 2 India 3 years 6 years 963
D-II-1 M WES/S c.[1147G4A];
[1147G4A]
p.[G383R];
[G383R]
7 1–3 Spain 10
months
w (4 years) 965y
E-II-2 F AM/S c.[1407C4G];
[1407C4G]
p.[N469K];
[N469K]
9 1–3 Lebanon 2 years 17 years 2,280
E-II-3 F AM/S c.[1407C4G];
[1407C4G]
p.[N469K];
[N469K]
9 1–3 Lebanon 2 years 16 years 3,830
E-II-4 M WES/AM/S c.[1407C4G];
[1407C4G]
p.[N469K];
[N469K]
9 1–3 Lebanon 2 years 9 years 1,260
AM, autozygosity mapping; F, female; M, male; NA, not available; S, Sanger sequencing; WES, whole-exome sequencing.
Individual families are numbered A to E with each affected sibling listed.
*All patients were from consanguineous families and were shown to be homozygous for the mutations detected. WES, AM, S, Nucleotide (c.) and amino-acid (p.) changes refer to transcript 2
(NM_015359.4) and protein isoform 2 (NP_056174.2) and are listed together with the exon and isoform affected.
wDeceased, NA
zDNA of this subject was not available for mutation testing. Her clinical phenotype was similar to her sibling, suggesting that they were both affected by the same disorder. Normal reference range for
whole-blood Mn is given in brackets.
yMn estimation performed in different hospital laboratory, reference range o145.6 nmol l 1.
Table 2 | Whole-blood Mn levels are raised in SLC39A14 deﬁciency.
ngml 1 Control F98V E105X Father Mother Reference
Mn 6.69–11.29 159 445 15.1 12.2 5–12.8 (ref. 40)
Fe 409–462 434 397 370 386 236–614 (ref. 41)
Cu 635–1,096 1,130 944 770 1,108 590–1,470 (ref. 41)
Zn 4,364–5,284 5,076 4,580 5,804 5,424 4,800–7,800 (ref. 41)
Cd 0.35 1.42 0.18 0 0.89 0.15–2.04 (ref. 40)
Table showing whole-blood metal levels for two affected individuals (F98V and E106X), three healthy control subjects, parents heterozygous for the E105X mutation and published reference ranges40,41.
While Mn levels are signiﬁcantly raised in both patients, other metal levels are within the normal range. Abnormal Mn levels are indicated in italics.
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(Supplementary Fig. 13). Despite abnormal Mn levels, slc39a14U801
mutants survived into adulthood without any obvious
morphological or developmental defects.
Exposure of homozygous slc39a14U801 mutants to a sublethal
MnCl2 concentration (50 mM) from 2 to 5 dpf led to a much
greater accumulation of Mn relative to wild-types at 5 dpf
(Fig. 6a). Homozygous slc39a14U801 larvae also showed increased
sensitivity to Mn-induced toxicity; the median lethal concentra-
tion (LC50) of MnCl2 was signiﬁcantly lower for mutant
compared with wild-type larvae, and analysis of the relative
median potency of MnCl2 (1.75, 95% conﬁdence interval 1.2–2.9)
suggested MnCl2 to be 1.75 times more lethal for mutant than for
wild-type larvae (Fig. 6c, Supplementary Fig. 14). A locomotor
assay49 conﬁrmed that exposure of homozygous slc39a14U801 but
not wild-type larvae to MnCl2 leads to a prominent reduction in
their average locomotor activity (Fig. 6d). These analyses
of the slc39a14U801mutant demonstrate that loss of Slc39a14
function causes Mn dyshomeostasis similar to observations in
humans.
Cerebral Mn deposition induces transcriptional changes. To
determine the major site of Mn accumulation in slc39a14U801
mutants, Mn levels were determined in brain and abdominal
viscera (intestine, liver, pancreas and spleen) of adult zebraﬁsh
at 1 year of age. Mn levels were eight times higher in brains
from homozygous slc39a14U801 ﬁsh compared with wild-type,
whereas no signiﬁcant differences in the Mn content of
abdominal viscera were observed (Fig. 7a). Fe, Zn and Cd levels
were unchanged in mutant brain tissue while there was a small
increase in Fe in abdominal viscera (Supplementary Fig. 15).
Thus, the brain represents the main organ of Mn deposition in
slc39a14U801 zebraﬁsh. To assess whether loss of Slc39a14
function and cerebral Mn deposition leads to differential
expression of other Mn uptake transporter genes, transcript
levels of transferrin receptor 1 (tfr1a, tfr1b), divalent metal
transporter 1 (DMT1) and slc39a8 were compared between
mutant and wild-type adult brains and whole larvae
(Supplementary Fig. 16). While most of these genes showed no
statistically signiﬁcant changes, transcript levels of tfr1b were
signiﬁcantly lower in slc39a14U801 mutant brains. On the other
hand, MnCl2 overexposure of wild-type and mutant larvae led
to upregulation of tfr1b but downregulation of slc39a8 expres-
sion. These results suggest that tfr1b and slc39a8 are indeed
involved in the regulation of Mn homeostasis, probably with
different roles within different tissues.
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Figure 2 | SLC39A14 deﬁciency causes hypermanganesemia and neurodegeneration that responds to chelation treatment with Na2CaEDTA. (a) Liver
MRIs of a patient with SLC30A10 deﬁciency, individual E-II-2 with SLC39A14 mutations and a control subject. The extensive signal hyperintensity on
T1-weighted imaging caused by hepatic Mn deposition in SLC30A10 deﬁciency is absent in individual E-II-2. There is only a subtle degree of T1-
hyperintensity when compared with the control subject. Signal intensity of the liver (yellow arrow) was compared with that of the spleen (blue arrow).
(b) Brain histology from post-mortem examination of subject D-II-1. Sections of globus pallidus and dentate nucleus stained with hematoxylin and eosin
(H&E) show marked neuronal loss with only occasional remaining neurons (arrow) accompanied by reactive astrocytosis (shown within the ribbon of the
dentate nucleus (between arrows)). Scale bar, 100 mm. Luxol fast blue/cresyl violet stain of a section of the cerebral white matter demonstrates patchy loss
of myelin associated with coarse vacuoles (arrow). Scale bar 200mm. (c) Graph showing whole-blood Mn levels and urinary Mn excretion over four
courses of Na2CaEDTA treatment in individual E-II-2. Arrows indicate timing of Na2CaEDTA courses (day 1, 34, 52 and 84). Administration of Na2CaEDTA
causes a signiﬁcant increase in urinary Mn excretion (red) accompanied by a drop in whole-blood Mn levels (blue).
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Figure 3 | SLC39A14 isoforms 1 and 2 show differences in tissue expression, Mn uptake and transcriptional regulation. (a) Immunostaining for
SLC39A14 (all isoforms) in healthy control liver shows cell membrane expression (yellow arrow) and punctate cytoplasmic staining (black arrow); scale bar,
50mm; Abcam anti-SLC39A14 antibody (ab106568, 1:100); and in globus pallidus (GP) from a healthy control shows positively stained large neurons
(black arrow); scale bar, 100mm; Novus anti-SLC39A14 antibody (NBP1-81551, 1:1,000). (b,c) Confocal images demonstrating the subcellular localization of
ﬂuorescently tagged human SLC39A14 isoform 1 (b) and isoform 2 (c) expressed in zebraﬁsh embryos. Immunostaining for EGFP and mCherry at 6 hpf shows
that both isoforms are expressed at the cell membrane (co-localization with membrane mCherry) and in the cytoplasm. 40 ,6-diamidino-2-phenylindole (DAPI)
was used as a nuclear stain. Scale bar, 50mm. (d) RT–PCR of adult and fetal human tissues showing differences in mRNA expression between isoform 1
(ubiquitous expression in the tissues examined) and isoform 2 (* absent expression in brain, heart, skeletal muscle and skin). Amplicons for isoform 1 and 2
span 139 bp and 109bp, respectively. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used as a housekeeping gene. L, 100bp ladder
(Promega). (e) Graph showing Mn uptake in HEK-293 cells transiently transfected with wild-type SLC39A14 isoform 1 and 2, and empty pCS2þ vector
following 15 and 30min of MnCl2 (1mM) exposure. Both isoforms facilitate Mn uptake. Cells transfected with isoform 2 have signiﬁcantly higher Mn levels
(P¼0.009). Data are presented as means±s.d. from two independent experiments. Statistical analysis was performed using one-way ANOVA (P¼0.0002
(15min), P¼0.0002 (30min)) and Tukey’s multiple comparison test (***Po0.001). (f) Graph showing slc39a14 transcript levels assessed by qRT–PCR in 5
dpf zebraﬁsh larvae after exposure to 500mMMnCl2 for 24h. Overall transcript levels are increased (P¼0.035). Transcript levels of isoform 1 are unchanged
(P¼0.41) while those of isoform 2 show a 4.6-fold increase (P¼0.005). Data are presented as means±s.d. from three independent experiments. Statistical
analysis was performed using Student’s two-tailed t-test on individual DCt values (*Po0.05, **Po0.01). ANOVA, analysis of variance.
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Figure 4 | In vitro expressed mutant SLC39A14 shows compromised Mn uptake despite normal subcellular localization. (a) Immunoblot of whole-cell
lysates of stably transfected HEK-293 cells showing expression of the wild-type and three mutant SLC39A14 proteins. Actin was used as a loading control.
(b) Quantiﬁcation of SLC39A14 protein levels relative to actin expression revealed no signiﬁcant difference between wild-type and mutant SLC39A14. Data
are presented as means±s.d. from three repeat experiments. Statistical analysis was performed using one-way ANOVA (P¼0.071). (c,d) Confocal images
of stably transfected HEK-293 cells expressing FLAG-tagged SLC39A14 (green) showing that wild-type and mutant transporters co-localize with wheat
germ agglutinin (WGA)-labelled plasma membrane (red) in (c) non-permeabilized HEK-293 cells and show additional intracellular localization in (d)
permeabilized HEK-293 cells. Nuclei are stained with DAPI. Scale bars, 10mm. (e) Mn inﬂux studies in HEK-293 cells stably expressing wild-type (WT) and
mutant forms of SLC39A14 show a decrease in Mn uptake for all SLC39A14 mutants (P¼0.000 [F98V], P¼0.000 [G383R], P¼0.02 [N469K]. Data are
presented as means±s.d. from three technical replicates. Statistical analysis was performed using one-way ANOVA (P¼0.000) and Tukey’s multiple
comparison test (*Po0.05, ***Po0.001). ANOVA, analysis of variance.
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Figure 5 | Zebraﬁsh slc39a14 is expressed during early zebraﬁsh development and signiﬁcantly reduced in slc39a14U801 mutants. (a) RT–PCR showing
slc39a14 expression between 3 and 120 hpf in zebraﬁsh. L, 100 bp ladder (Promega). (b) Whole-mount in situ hybridization using a DIG-labelled antisense
RNA probe showing slc39a14 expression in the proximal convoluted (black arrows) and straight (red arrows) pronephric tubules in zebraﬁsh larvae at 4 dpf.
Top, lateral view; bottom, dorsal view. Scale bar, 200 mm. (c) DNA sequence of the region within exon 5 of slc39a14 targeted by a CRISPR guide RNA is
highlighted in yellow and the 2-bp deletion introduced in the slc39a14U801 mutant indicated by dashes. Pam sequence underlined. (d) qRT–PCR
demonstrates a 2.2-fold reduction in slc39a14 expression in homozygous slc39a14U801 mutants (*P¼0.0117). Primers were designed to detect all slc39a14
transcripts (Supplementary Table 4). Ef1a was used as a reference gene. Data are presented as means±s.d. from three independent experiments. Statistical
analysis was performed using Student’s two-tailed t-test on individual DCt values (*Po00.5).
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Figure 6 | Loss of slc39a14 function in zebraﬁsh leads to increased Mn accumulation and sensitivity as well as impaired locomotor behaviour. (a) Mn
levels assessed in homozygous slc39a14U801 and wild-type (WT) larvae show that mutant larvae have signiﬁcantly raised Mn levels at 5 dpf (P¼0.001)
and 14 dpf (P¼0.0002), and Mn accumulation on MnCl2 exposure (50 mM from 2 dpf) is signiﬁcantly higher in mutant compared with WT larvae
(P¼0.000) at 5 dpf. Measurements were taken from pools of 10 larvae. Data are presented as means±s.d. from a minimum of ﬁve independent
experiments. Statistical analysis was performed using Student’s two-tailed t-test (***Po0.001). (b) Graph showing Fe, Zn and Cd levels in 14 dpf mutant
and WT larvae. Levels of all three metals are not signiﬁcantly different between the two groups (P¼0.906 [Fe], P¼0.257 [Zn], P¼0.834 [Cd]).
Measurements were taken from pools of 10 larvae. Data are presented as means±s.d. from ﬁve independent experiments. Statistical analysis was
performed using Student’s two-tailed t-test (NS, not signiﬁcant). (c) Graph presenting the lethality in homozygous slc39a14U801 and WT larvae at 5 dpf on
MnCl2 exposure between 2 and 5 dpf. Median lethal concentration (LC50) of MnCl2 determined by Probit regression analysis was 661 mM for WT (95%
conﬁdence interval (CI) 548–808mM) and 377mM (95% CI 313–455mM) for mutant ﬁsh. Data are presented as means±s.e.m. from nine independent
experiments. (d) Locomotor behaviour studies of homozygous slc39a14U801 and WT larvae show that in unexposed conditions there is no signiﬁcant
difference in locomotor activity; and on MnCl2 exposure, locomotor activity is markedly reduced in mutant larvae compared with WT. The locomotor
behaviour was tracked during 4 and 7 dpf using automated analysis software. s/min, movement in seconds per minute. Data are presented as
means±s.e.m. 12 larvae were analysed per condition. Statistical analysis was performed using two way ANOVA (i, P¼0.18; ii, P¼0.000) (***Po0.001;
NS, not signiﬁcant). ANOVA, analysis of variance.
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Na2CaEDTA reduces the Mn load in slc39a14U801 mutants. To
examine whether Na2CaEDTA could reduce Mn accumulation in
homozygous slc39a14U801 larvae exposed to 50 mM MnCl2, we
performed daily cardiac injections of Na2CaEDTA from 2 to 4
dpf. Na2CaEDTA lowered Mn levels similar to those of wild-type
ﬁsh, conﬁrming the Mn chelating property of Na2CaEDTA
(Fig. 7b). Addition of the chelator to the ﬁsh water did not alter
Mn levels (Supplementary Fig. 17) probably due to its poor
absorption by the skin and gastrointestinal tract. These data
indicate that the slc39a14U801 mutant both recapitulates the
human phenotype and offers an effective assay for chelator drug
efﬁcacy.
Discussion
In this study, we have identiﬁed a novel autosomal recessive
disorder of Mn homeostasis caused by homozygous mutations in
SLC39A14 that lead to early-onset rapidly-progressive
parkinsonism–dystonia and neurodegeneration. Identiﬁed muta-
tions are predicted to affect transporter function either through
nonsense-mediated mRNA decay, protein truncation or impair-
ment of transporter activity. Moreover, we have generated and
characterized a zebraﬁsh slc39a14U801 mutant line that recapitu-
lates aspects of the human disease, providing novel insights into
Slc39a14 function and facilitating further elucidation of disease
mechanisms and drug screening.
SLC39A14 belongs to the SLC39 group of divalent metal
transporters. Prior to this study, there was considerable
uncertainty with respect to the in vivo speciﬁcity of this
transporter. Unlike most SLC39 proteins that are speciﬁc for
Zn in vitro data suggested that SLC39A14 could transport Mn, Fe
and Cd31,37,38. Our data indicate that in vivo, the major role for
SLC39A14 is to transport Mn. Homozygous slc39a14U801
zebraﬁsh accumulate high levels of Mn and show increased
sensitivity to Mn toxicity while levels of Fe, Zn and Cd remain
unaffected. This is consistent with our ﬁnding that blood
metal levels of Fe, Zn and Cd are unaffected in patients with
SLC39A14 mutations. Consequently, SLC39A14 joins SLC30A10
(refs 21–23) and SLC39A8 (ref. 4,5) as clinically important,
conserved and critical regulators of Mn homeostasis in vertebrates.
Cerebral Mn deposition in patients with SLC39A14 mutations
is associated with characteristic MRI brain appearances similar to
those observed in SLC30A10 deﬁciency. Both disorders present
with a progressive extrapyramidal phenotype and neurodegen-
erative features, including neuronal loss and spongiosis in the
globus pallidus, as well as myelin and axonal loss throughout the
white matter50. However, differences do exist between the two
disorders. Individuals with SLC39A14 deﬁciency do not develop
polycythaemia or abnormal iron indices, and liver function is
preserved even in cases with advanced neurological disease.
It is plausible that the primary function of SLC39A14 in
humans is hepatic Mn uptake for subsequent biliary excretion
through SLC30A10. Certainly, MR liver imaging is consistent
with lack of hepatic Mn deposition in patients with SLC39A14
deﬁciency. The high level of SLC39A14 expression in liver
tissues (observed in this study and previously32,36) further
substantiates this hypothesis. Mn exposure in mice also causes
a marked increase in hepatic SLC39A14 mRNA expression,
further highlighting the role of SLC39A14 in hepatic Mn uptake
under a high Mn load51. This hypothesis is reinforced by the
observation that subject C-II-2 carries mutations that solely affect
isoform 2. The absence of brain expression of isoform 2 suggests
that the primary defect of Mn clearance does not occur in the
brain and that cerebral Mn deposition arises secondarily due to
the increased systemic Mn load. As the main regulatory
organ involved in Mn homeostasis in humans, the liver seems
most likely to play the crucial role in the disease mechanism.
Slc39a14 / mice furthermore show transcriptional upregu-
lation of Slc30a10 expression, suggesting that Slc30a10 and
Slc39a14 transporters indeed act in partnership for efﬁcient
hepatic Mn detoxiﬁcation52. We postulate that loss-of-function
mutations in SLC39A14 in humans lead to impaired hepatic Mn
uptake with resultant hypermanganesemia and downstream
neurotoxic effects (Fig. 8).
Whether SLC39A14 is essential for Mn uptake in other tissues
remains to be clariﬁed. The ubiquitous expression pattern that we
have conﬁrmed for isoform 1 suggests a role for SLC39A14 in a
wide range of tissues. Although SLC39A14 is expressed in the
intestine, the major site of Mn uptake, intestinal Mn uptake
appears to be preserved in this disease as clinically we do not see
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Figure 7 | Mn accumulates in the brain of slc39a14U801 mutants and can
be lowered by Na2CaEDTA. (a) Tissue Mn levels of wild-type (WT) and
homozygous slc39a14U801 zebraﬁsh at 1 year of age show that mutant
brain tissue accumulates signiﬁcantly higher amounts of Mn (P¼0.0012)
while no differences are evident in the Mn content of abdominal viscera
(P¼0.116). Measurements were taken from pools of four brains/
abdominal viscera. Data are presented as means±s.d. from two
independent experiments. Statistical analysis was performed using
Student’s two-tailed t-test (**Po0.01; NS, not signiﬁcant). (b) Graph
showing the effect of Na2CaEDTA injections on Mn levels in homozygous
slc39a14U801 larvae. Mutant larvae exposed to 50 mM MnCl2 from 2 to 5
dpf were injected into the heart with 5 or 50 ng of Na2CaEDTA at 2, 3 and
4 dpf, resulting in a reduction of Mn levels to that of wild-type larvae
(P¼0.000 (WT untreated versus mutant untreated), P¼0.001 (mutant
untreated versus 5 ng), P¼0.001 (mutant untreated versus 50 ng)).
Measurements were taken from pools of 10 larvae. Data are presented as
means±s.d. from a minimum of three independent experiments.
Statistical analysis was performed using one-way ANOVA (P¼0.000)
and Tukey’s multiple comparison test (**Po0.01, ***Po0.001). ANOVA,
analysis of variance.
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deﬁciency of Mn. Similarly, Mn is deposited in the brain,
suggesting that transporters other than SLC39A14 facilitate
cerebral Mn uptake. Several alternative Mn uptake transporters
may compensate for loss of SLC39A14 function. These include
DMT1, TfR1, SLC39A8, Mn citrate shuttle, glutamate receptors
and various calcium channels/ATPases that have been implicated
in Mn transport at the cell membrane either in the brain or the
intestine53. Quantitative gene expression analysis suggests that
tfr1b, one of two tfr1 paralogues in zebraﬁsh and the main
cerebral tfr1 gene54, may be involved in facilitating brain Mn
uptake in this disorder. Excess Mn in the brain is likely to lead to
downregulation of transporter gene expression. On the other
hand, increased transcript levels of tfr1b on Mn exposure in
whole larvae suggests that the role of this gene may vary between
tissues.
Our analyses of the subcellular localization of human
SLC39A14 in zebraﬁsh embryos and HEK-293 cells demonstrate
that SLC39A14 is not only present on the cell membrane but also
intracellularly. This is consistent with previous studies in HepG2
cells where SLC39A14 was detected at the plasma membrane and
in endosomes38. Hence, SLC39A14 might be required for intra-
cellular trafﬁcking of Mn and its transport into speciﬁc organelles.
This concurs with a recent study showing that SLC39A14
facilitates endosomal trafﬁcking of zinc in enterocytes55. Subcel-
lular deﬁciency of Mn may therefore also contribute to the
neuropathology in SLC39A14 deﬁciency.
Similar to humans, the brain is the main organ of Mn
deposition in zebraﬁsh slc39a14U801mutants. Moreover,
slc39a14U801 larvae demonstrate impaired locomotor behaviour
on Mn exposure. Recently, environmental Mn exposure has been
linked to impaired dopamine neuromodulation in zebraﬁsh56.
The mechanisms that lead to reduced locomotor activity in
slc39a14U801 larvae require further studies to elucidate whether,
similarly, the observed changes are due to speciﬁc Mn neuro-
toxicity. Unlike humans, however, slc39a14 is not expressed in the
liver during early larval zebraﬁsh development. The prominent
expression of slc39a14 in the pronephric ducts indicates that the
kidney is likely to regulate Mn homeostasis in zebraﬁsh larvae.
I.v. Na2CaEDTA signiﬁcantly increases urinary Mn excretion
and lowers blood Mn levels in affected individuals. Similarly, in
slc39a14U801 zebraﬁsh cardiac injection of Na2CaEDTA led to
lower Mn levels compared with those of untreated mutants.
Nevertheless, clinical response varied between the two individuals
given chelation therapy. Subject C-II-2 who was commenced on
Na2CaEDTA early in the disease course showed a remarkable
response with restoration of ambulation, whereas subject E-II-2,
severely affected by late stage disease, has continued to clinically
deteriorate, even though blood and urine Mn levels suggested
mobilization of Mn stores. We know from SLC30A10 deﬁciency
that despite extensive neuronal damage Mn toxicity phenotypes
are to a great extent reversible43. Although chelation therapy can
be efﬁcacious, it could potentially lead to a worsening of
neurological symptoms due to mobilization of Mn with a shift
into the brain similar to observations in Wilson’s disease. Indeed,
10–50% of patients with neurologic Wilson’s disease deteriorate
during the initial phase of treatment with D-Penicillamine57.
Furthermore, the type of mutation may have an impact on
treatment response. While individual C-II-2 has a homozygous
mutation that only affects SLC39A14 isoform 2 all isoforms are
affected in subject E-II-2.
We have shown that the tissue localization of isoform 1 and 2
of SLC39A14 differs and that there may be differences in
functional activity. Whilst isoform 1 is ubiquitously expressed
with high levels of expression evident in the brain, isoform 2
shows a restricted expression pattern including liver, kidney and
intestine – organs involved in the regulation of metal ion
homeostasis. As reported previously for murine Slc39a1432, our
Mn uptake studies in HEK-293 cells conﬁrm that human isoform
2 has a greater ability to transport Mn than isoform 1.
Furthermore, Mn-dependent transcriptional regulation of
SLC39A14 expression appears to only affect isoform 2. In
zebraﬁsh mRNA expression of transcript 2 is upregulated on
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Figure 8 | Proposed disease mechanism in patients with SLC39A14 mutations. (a) Under normal conditions nutritional Mn (red) is absorbed in the
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Mn loading whereas that of transcript 1 remains unchanged.
Similarly, transcription of SLC30A10 is regulated by Mn and the
induction of SLC30A10 expression on Mn exposure is likely to
reduce the body Mn load through promotion of hepatic
excretion22. These ﬁndings suggest that there may be speciﬁc
roles for the individual SLC39A14 isoforms that might also
contribute to differences in treatment response.
Whilst Mn levels have not been assessed in Slc39a14 / mice,
alterations in Zn and Fe absorption and trafﬁcking have been
reported55,58. Slc39A14 / mice demonstrate enhanced hepatic
iron uptake via transcriptional upregulation of DMT1 and TfR-1
(ref. 58). This is consistent with our ﬁnding of increased Fe
content in abdominal viscera of slc39a14U801 zebraﬁsh. It is
possible that increased DMT1 and TfR-1 expression occurs in
response to the high Mn load and indeed tfr1b expression
increases on Mn exposure in both wild-type and mutant zebraﬁsh
larvae. Both of these transporters transport Mn and Fe
interdependently26,30. A recent study of Slc39a14 / mice
suggests that Slc39a14 is also instrumental in the uptake of Cd
into the liver with hepatic Cd levels being diminished while
other organs including kidney, gut and lung showing Cd
accumulation52.
Our results show that SLC39A14, alongside SLC30A10, is a
pivotal Mn transporter required for Mn clearance and main-
tenance of Mn homeostasis in vertebrates. Our ﬁndings expand
our understanding of Mn transport and its regulatory mechan-
isms, and highlight its importance in neurodegenerative disease
processes. SLC39A14 is part of a group of Mn transporters that
regulates the intricate network of Mn homeostasis. Further
studies of the function of this transporter might shed new light on
our understanding of how Mn toxicity may contribute to the
pathogenesis of PD, with Mn dyshomeostasis not only being
observed in inherited disorders of Mn transport and environ-
mental manganism, but also playing an important role in
heritable forms of PD that show greater susceptibility to Mn
toxicity6. However, treatment of Mn neurotoxicity remains
unsatisfactory. The slc39a14U801 zebraﬁsh mutant has the
potential to illuminate the mechanisms of Mn toxicity and
provide new avenues for drug discovery for both rare and
common neurodegenerative disorders associated with Mn
toxicity.
Methods
Subjects. A cohort of patients with extrapyramidal movement disorder, hyper-
manganesemia and typical MRI brain appearances of Mn deposition (T1-weighted
hyperintensity of the globus pallidus and white matter, T2-weighted globus pallidus
hypointensity) was analysed in this study. Detailed clinical case descriptions are
listed in the Supplementary Information. Written informed consent for DNA
storage and genetic analyses was obtained from all subjects/parents. Consent for
post-mortem studies of individual D-II-1 was obtained from the parents. The study
was approved by the local ethics committees including the West London Research
Ethics Committee at the UCL Institute of Child Health, the IRB protocol #7232 at
the Oregon Health & Science University, and HREC 10/CHW/114 and 10/CHW/
45 at the Kids Research Institute at the Children’s Hospital at Westmead.
Reagents. Chemicals were purchased from Sigma-Aldrich unless stated otherwise.
WES and linkage analysis. Family B and D. Library construction and capture
hybridization were performed using either the SureSelect XT Human All Exon V4
or V5 Kit (Agilent Technologies) according to the manufacturer’s protocol. Sam-
ples were barcoded post-capture to allow for multiplexing of four samples per
HiSeq2000 lane. Cluster generation took place on the Illumina cBot according to
the manufacturer’s recommendations. Sequencing occurred on the Illumina
HiSeq2000 using the reagents provided in the Illumina TruSeq PE Cluster Kit v3
and the TruSeq SBS Kit-HS (200 cycle) kit. On average, 96 million pass ﬁlter
paired-end reads per sample were generated for a mean coverage of 78% at a read
depth of 20 . Variants were called based on dbSNP139 (ref. 59) and annotation
based on SeattleSeq Annotation 137 version 8.01. Filtering was performed using the
in-house developed software GEMapp60.
Family A and E. In the three affected individuals of Family E, a genome-wide
linkage scan using the Affymetrix 250 k Sty1 SNP mapping array was carried out
on an Affymetrix GeneChip ﬂuidics station 450 according to the manufacturer’s
instructions. Fluorescence intensities were quantiﬁed using an Affymetrix array
scanner 3000-7G and the data collected by the Affymetrix GeneChip Operating
Software (GCOS) v1.4 (all Affymetrix, Inc.). GTYPE software for BRLMM analysis
was used to ascertain genotypes of the samples, which were analysed further using
HomozygosityMapper software (see URLs). Signiﬁcant regions of common
homozygosity (42Mb) were evaluated by genotyping with microsatellite markers
in more detail using an ABI 3,730 DNA Analyzer and Genemapper v3.0 software
(Applied Biosystems). The candidate region on chromosome 8 was also genotyped
in all available family members of Family A. Primer sequences and the physical
order of the markers were obtained from the NCBI database and the UCSC
browser (see URLs), respectively. WES was undertaken in affected individual
E-II-4. Protein coding exons were captured using SureSelect All Exon 50Mb Target
Enrichment System/SureSelect human All Exon kit (v2; Agilent Technologies).
Sequencing was performed on the Illumina GaIIx with 76 bp paired-end reads.
Alignment of the obtained sequences to the reference genome (hg19 build) was
carried out with Novoalign (Novocraft Technologies Sdn Bhd). Duplicated reads
(caused by PCR clonality or optical duplicates) and reads mapping to multiple sites
were omitted. Single nucleotide substitutions and small insertion deletions were
detected and quality ﬁltered within the SamTools software package and in-house
software tools. After ﬁltering out all calls with a read coverageo4 and a phred-
scaled SNP quality of o20, variants were annotated with respect to genes and
transcripts with the Annovar tool. Identiﬁcation of novelty of variants was achieved
by comparison to dbSNP132, 1,000 Genomes SNP calls and a subset of 250 control
exomes sequenced and analysed by the same method.
Variant validation and mutation analysis. For sequence validation, mutation
screening and segregation analysis, the coding exons and intron/exon boundaries
of SLC39A14 (covering transcripts NM_001128431.2, NM_015359.4 and
NM_001135154.1) were PCR ampliﬁed from genomic DNA and sequenced
bi-directionally using the Big Dye Terminator Cycle Sequencing System
(Applied Biosystems) and run on an ABI PRISM 3,730 DNA Analyzer. Primers
and PCR conditions are listed in Supplementary Table 3. Population frequencies of
identiﬁed sequence changes were obtained from the dbSNP, 1,000 Genomes Project
and ExAC databases (access date January 2016).
ICP-MS analysis of metal ions. About 50ml of EDTA blood were added to
1.95ml of 3% nitric acid (Fisher) and incubated at 85 C for 4 h. After cen-
trifugation, the supernatant was analysed by ICP-MS. To determine metal levels in
zebraﬁsh larvae, 10 larvae of the same genotype, terminally anaesthetized with MS-
222, were pooled and washed several times with dH2O. Samples were digested in
1ml 3% nitric acid at 85 C overnight followed by a ﬁnal 95 C incubation step for
2 h. Tissues (brain and abdominal viscera including intestine, liver, pancreas and
spleen) dissected from adult zebraﬁsh were digested in concentrated nitric acid at
room temperature overnight and subsequent incubation at 95 C for 30min.
Samples were diluted with ICP-MS grade H2O (Fluka) to a ﬁnal nitric acid con-
centration of 3%. Samples from four zebraﬁsh of the same genotype were combined
to ensure metal concentrations exceeded the limit of detection. Transiently
transfected HEK-293 cells (transfection was carried out 24 h prior analysis) or
stable cell lines were incubated in culture medium containing 1 mM MnCl2 for
15min and 30min, respectively. Following two washes with ice-cold phosphate
buffered saline (PBS), cells were harvested in 500ml PBS using a cell scraper and
transferred to a microcentrifuge tube. The cell pellets were washed once in 250 ml
ICP-MS grade H2O and lysed by repeated freeze-thawing using an ethanol dry ice
and 37 C water bath. The protein concentration was determined using BCA
reagent (Thermo Scientiﬁc) and the cell lysates digested in nitric acid at a ﬁnal
concentration of 3% in a ﬁnal volume of 1ml. Digestion was carried out at 85 C
overnight and 95 C for 2 h the following day. The metal ion isotopes Mn-55,
Fe-56, Zn-66 and Cd-111 were measured by an Agilent 7,500 Series ICP-MS in
Helium collision mode. Calibration solutions were prepared for each element
between 0 and 200 ngml 1.
Histopathology and SLC39A14 immunohistochemistry. Parafﬁn-embedded
brain tissue sections were analysed using routine diagnostic histological stains.
SLC39A14 immunohistochemistry was performed on control liver sections using a
rabbit polyclonal antibody to SLC39A14 (1:100, ab106568, Abcam) on a Leica
Bond Max automated system using commercial reagents. Bond Epitope Retrieval
Solution 2 (pHB9 (Leica) was used for antigen retrieval and 3,30-diaminobenzi-
dine (DAB)/horseradish peroxidase (HRP) for visualization. Immunohistochem-
istry on normal human brain tissue from the Oregon Brain Bank was performed by
hand using the rabbit polyclonal anti-SLC39A14 antibody (1:1,000; NBP1-81551,
Novus) with DAB/HRP development as above. This antibody was also used to
conﬁrm expression in control liver tissue that was observed using the Abcam
antibody (not shown).
RNA extraction and qRT–PCR. Total RNA was extracted from tissues or pools of
30 zebraﬁsh embryos/larvae using the TRIzol protocol (Life Technologies). Total
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RNA from human small intestine and foetal liver was purchased from Clontech
and Stratagene, respectively. cDNA was synthesized with SuperScript III First
Strand Reverse Transcriptase (Life Technologies) using 1 mg total RNA per
reaction. In addition, a human cDNA panel from heart, brain, lung, liver, kidney
and pancreas was purchased from Clontech. Foetal cDNA from placenta, skin,
brain, heart, kidney, intestine and liver were kindly provided by the BabyBioBank
at UCL Institute of Child Health, London, UK. Primers and thermocycling
conditions used for RT–PCR are listed in Supplementary Table 4.
Real-time PCR was carried out on a CFX96 Touch Real-Time PCR Detection
System (Bio-Rad) with the following thermocycling conditions: 2-min initial
denaturation at 94 C followed by 40 cycles of 15 s at 94 C, 30 s at 60 C, 30 s at
72 C. Reactions (ﬁnal volume of 20 ml) contained 10ml GoTaq qPCR Master Mix
(Promega), 2 ml cDNA and 500 nM of each primer. All reactions were performed in
triplicates. Primer efﬁciency (10 1/gradient) was calculated by standard curve
analysis using 1:5 serial dilutions over ﬁve samples. Primer sequences and
efﬁciencies are listed in Supplementary Table 5. Relative quantiﬁcation of gene
expression was determined using the 2DCt method61, with elongation factor 1a
(ef1a) as a reference gene.
Cloning of human SLC39A14. (i) For transient transfection of HEK-293 cells and
expression studies in zebraﬁsh embryos: the coding sequences of human SLC39A14
transcript 1 and 2 were ampliﬁed from foetal liver cDNA with Q5 High Fidelity
DNA polymerase (NEB) according to the manufacturer’s recommendations
using phosphorylated primers (Fwd 50-CTGGGACCTTGCGGTGAG-30 and Rev
50-CTTCCAGTCCCACAGGCTCT-30) and cloned into pCS2þ vector linearized
with StuI (NEB) and dephosphorylated with thermosensitive alkaline phosphatase
(Promega). Escherichia coli XL10 Gold Ultracompetent Cells (Agilent Technolo-
gies) were transformed with ampliﬁcation products and the success of mutagenesis
conﬁrmed by DNA sequencing. To generate C-terminally EGFP-tagged constructs
of SLC39A14 the In-Fusion HD Cloning Kit (Clontech) was used. In brief, the
above pCS2þ constructs containing the open reading frame of SLC39A14 tran-
script 1 and 2 were ampliﬁed by PCR. The EGFP sequence together with a ﬂexible
linker (50-GGTGGATCAGGAGGTGGCGGAAGTGGTGGAGGGAGCTCAGG
A-30) was PCR-ampliﬁed from a construct available from previous studies using
primers with 15 bp overhangs homologous to the pCS2þ constructs (primer
sequences in Supplementary Table 6). In-Fusion cloning reactions and transfor-
mation of Stellar Competent E. coli cells (Clontech) were performed according to
the manufacturer’s instructions and construct sequences veriﬁed by Sanger
sequencing.
(ii) For stable transfection of HEK-293 cells: the pCMV-Entry Vector encoding
hSLC39A14 (isoform 1) with myc-FLAG sequence at the C-terminal region was
purchased from Origene. Site-directed mutagenesis was performed to generate
hSLC39A14 mutants by using the QuikChange Lightning Kit (Stratagene) (primers
in Supplementary Table 7). Mutagenesis products were veriﬁed by DNA
sequencing. Thus generated plasmids containing each of the three missense
mutations (F98V, G383R and N469K) were utilized for stable transfection of HEK-
293 cells.
Overexpression of SLC39A14 in zebraﬁsh embryos. Following linearization of
SLC39A14-EGFP constructs with SnaBI (NEB), capped mRNA was generated
using the mMessage mMachine Sp6 Transcription Kit (Life Technologies) and
puriﬁed using the RNeasy Mini Kit (Qiagen). About 50 pg of either SLC39A14
mRNA (transcript 1/2) was co-injected with 50 pg mRNA encoding membrane
mCherry. Injected embryos were ﬁxed at 6 hpf in 4% paraformaldehyde at 4 C
overnight. Following several washes in PBS/0.1% Triton X-100 embryos were
blocked in 10% goat serum at room temperature for 1 h. This was followed by
incubation with primary antibody (chicken anti-GFP (1:500, ab13970, Abcam),
rabbit anti-RFP (1:1,000; PM005, MBL)) at 4 C overnight. Following washes in
PBS/0.1% Triton X-100, embryos were incubated in ﬂuorescent secondary antibody
(goat anti-chicken Alexa Fluor 488 (1:200, A-11039, Life Technologies), goat anti-
rabbit Alexa Fluor 568 (1:200, A-11011, Life Technologies)) at 4 C overnight.
DAPI (1:500, Life Technologies) was used for nuclear staining. Embryos were
mounted in 1.5% low melt agarose and imaged on a Leica TCS SPE confocal
microscope using a  25 0.95 water-immersion objective. Z-stacks were acquired
in 1-mm intervals and maximum-intensity projections generated with Fiji
software62.
Transient/stable transfection of HEK-293 cells. HEK-293 cells were grown in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) supplemented with 4.5 g l 1
glucose, 2mM L-glutamine, 10% FBS (PAA Laboratories) and MEM non-essential
amino-acid solution (Sigma) and maintained in an incubator at 37 C and 5% CO2.
For transient transfection, cells were transfected with 8 mg of plasmid DNA
(pCS2þ vector alone or pCS2þ vector containing SLC39A14 transcript 1 or 2)
using Lipofectamine 2,000 (Life Technologies) according to the manufacturer’s
instructions 24 h after seeding in six-well plates. To generate stable cell lines, HEK-
293 cells were transfected with 2 mg plasmid DNA (myc-FLAG-wild-type/
292T4G/1147G4A/1407C4G SLC39A14 transcript 1 in pCMV-Sport6 vector)
on day 1 using Effectene reagent (Qiagen), and on day 3 cells were selected with
DMEM containing 800mgml 1 Geneticin (G418). Selected clones were screened
by immunoblotting analysis with M2 anti-FLAG-HRP antibody (A8592, Sigma).
Positive cell clones were maintained in DMEM supplemented with 10% FBS and
800 mgml 1 G418. One clone per genotype was selected for downstream
experiments.
Immunoﬂuorescence of HEK-293 cells. For confocal studies, stably transfected
HEK-293 cells were incubated with Alexa Fluor 647 conjugate of wheat germ
agglutinin (1:200 Invitrogen) for plasma membrane labelling for 30min on ice.
Cells were ﬁxed with 4% paraformaldehyde (TAAB Laboratories Equipment Ltd.)
in PBS for 10min followed by washing with PBS and then quenching of free
aldehyde groups with ammonium chloride (50mM) for 10min. After blocking
with 10% foetal calf serum (FCS) in PBS for cell surface staining and 10% FCS and
0.1% Triton X-100 in PBS for permeabilized conditions for 30min, myc-FLAG-
tagged protein was immunostained with the mouse monoclonal antibody anti-Flag
M2 (1:500, F3165, Sigma) in PBS with 10% FCS (cell surface staining) and PBS
with 10% FCS and 0.1% Triton X-100 (permeabilized conditions) at 4 C overnight,
respectively. Subsequently, cells were washed with PBS and treated with goat anti-
mouse Alexa Fluor 488 secondary antibody (1:500, A-11001, Life Technologies) in
PBS with 10% FCS (cell surface staining) and PBS with 10% FCS and 0.1% Triton
X-100 (permeabilized conditions) for 1 h at room temperature followed by nuclear
staining with DAPI (1:5,000; Life Technologies). Coverslips were mounted with
ProLong Gold antifade reagent (Life Technologies) on glass slides. Microscopic
images were captured using a Leica TCS SP5 AOBS confocal microscope with a
 63/numerical aperture 1.3 oil immersion objective and  3 optical zoom; the
pinhole was set to 1 Airy unit. A series of optical sections were gathered and
analysed with the Fiji software62.
Immunoblot analysis. Stably transfected HEK-293 cells were washed twice with
cold PBS and lysed in NETT buffer (150mM NaCl, 5mM EDTA, 10mM Tris,1%
Triton X-100 and 1 Complete Mini protease inhibitor Mixture (Roche), pH 7.4).
Protein concentrations of the cell lysates were measured using the RC DC Protein
Assay kit (Bio-Rad). Cell lysates were mixed with 1 Laemmli buffer and incu-
bated for 30min at 37 C. Proteins were separated electrophoretically on an
SDS/10% polyacrylamide gel, transferred to nitrocellulose. Blots were incubated for
1 h in blocking buffer (5% non-fat dry milk in Tris-buffered saline-Tween 20) and
then probed for 1 h with mouse anti-FLAG-HRP, M2 (1:10,000; A8592) in blocking
buffer. To conﬁrm equivalent loading, blots were stripped for 15min in Restore
PLUS Western Blot Stripping Buffer (Thermo Scientiﬁc), blocked for 1 h and
reprobed with mouse anti-actin (1:10,000; MAB1501, Millipore) and then goat
anti-mouse secondary antibody conjugated to HRP (1:5,000; 12–349, Millipore).
Quantiﬁcation of SLC39A14 protein levels was carried out using ImageJ software.
To compare WT and mutant protein levels, intensity values of WT and mutant
bands of SLC39A14 and of actin as reference protein were determined. The ratio
between WT and mutant values of the reference protein was used as a normal-
ization factor. The mutant SLC39A14 values were then corrected by multiplying
them with the corresponding normalization factor. The expression of the mutant
protein was represented relative to the WT protein by dividing the corrected
mutant intensity values by WT intensity value.
Zebraﬁsh strains and husbandry. Zebraﬁsh (Danio rerio) were raised under
standard conditions at 28 C and staged according to the study by Kimmel et al63.
AB and Tu¨bingen wild-type strains were used in this study. For whole-mount
in situ hybridization, zebraﬁsh were treated with 0.002% phenylthiourea from 24
hpf to inhibit pigment formation. Ethical approval for zebraﬁsh experiments was
obtained from the Home Ofﬁce UK under the Animal Scientiﬁc Procedures Act
1986.
Zebraﬁsh whole-mount in situ hybridization. Zebraﬁsh larvae were ﬁxed in 4%
paraformaldehyde in PBS at 4 C overnight. A template for in vitro transcription
was generated by PCR using a reverse primer that contains a T7 promoter sequence
(Supplementary Table 8). A digoxygenin (DIG)-labelled antisense RNA probe of
940 bp was synthesized using the DIG labelling kit (Roche) and T7 RNA poly-
merase (Promega) according to the manufacturer’s recommendations. The probe
was detected with anti-DIG-AP antibody (1:2,000; 11093274910, Roche) and
nitroblue tetrazolium chloride (NBT)/5-bromo-4-chloro-30-indolyphosphate
(BCIP) substrate (Roche) according to published protocols64.
50 and 30 RACE of zebraﬁsh slc39a14. Total RNA was extracted from zebraﬁsh
larvae at 3 dpf and cDNA ends ampliﬁed using the FirstChoice RLM-RACE Kit
(Life Technologies) according to the manufacturer’s recommendations. Gene-
speciﬁc outer and inner primers are given in Supplementary Table 9. For
subsequent cloning, the inner primers were phosphorylated with T4 polynucleotide
kinase (Promega) and the PCR amplicons ligated into pBSK-vector linearized and
dephosphorylated with EcoRV (NEB) and thermosensitive alkaline phosphatase.
Plasmids were sequenced using M13 forward and reverse primers.
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Generation of zebraﬁsh slc39a14 null mutant. A blast search (https://blas-
t.ncbi.nlm.nih.gov/Blast/) to the zebraﬁsh genome suggested that only one slc39a14
orthologue (NC_007116.6) exists in zebraﬁsh. The CRISPR design tool (see URLs)
was used to identify a target region in exon 5 of zebraﬁsh slc39a14 that is
present in all transcripts (Fig. 4d)65. Oligonucleotides with compatible over-
hangs (Fwd 50-TAGGCCTTCGGGTTTGACCCCA-30 and Rev 50-AAACTGGGG
TCAAACCCGAAGG-30) were annealed as described by Hwang et al.47 and cloned
into the qDR274 vector (Addgene) digested with BsaI (NEB). The construct was
sequence-veriﬁed and gRNA generated using the HiScribe T7 High Yield RNA
Synthesis Kit (NEB) followed by DNase I (NEB) digestion and puriﬁcation with
RNeasy MiniKit (Qiagen). The Cas9 encoding plasmid pT3TS-nCas9n
(Addgene)48 was linearized with XbaI (NEB) and capped mRNA generated with
the mMessage mMachine T3 Transcription Kit (Life Technologies) followed by
polyadenylation with the Poly(A) Tailing Kit (Life Technologies). The synthesized
mRNA was puriﬁed using the RNeasy MiniKit. Cas9 mRNA and gRNA were co-
injected into one-cell stage embryos at a concentration of 200 ng and 75 ng per
embryo, respectively.
High-resolution melting analysis. Genomic DNA was extracted from single
embryos at 1 dpf or ﬁn clips from adult zebraﬁsh by incubation in 25 or 50 ml base
solution (1.25M KOH and 10mM EDTA) at 95 C for 30min followed by addition
of 25 or 50ml neutralization solution (2M Tris HCL). High-resolution melting
analysis66 was performed to assess the rate of mutagenesis in F0 and F1 embryos
and to identify adult F1 heterozygous carriers using Precision Melt Supermix
(Bio-Rad) on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad)
according to the manufacturer’s recommendations. Primers used were Fwd
50-CCCTGTATGTAGGCCTTCGG-30 and Rev 50-CCAAACACGACTGCGGA
CTTGG-30 . Data were analysed with Bio-Rad Precision Melt Analysis software and
the melt curve from injected zebraﬁsh compared with uninjected wild type
(Supplementary Fig. 12a). To assess the type of mutations introduced, a region of
330 bp around the CRISPR target site was PCR-ampliﬁed with Taq DNA
polymerase (Invitrogen) using primers Fwd 50-AACCCCAAACATCTGAACA
GT-30 and Rev 50-ACCGGAACAGACCATCAGTT-30 , cloned into pCRII-TOPO
vector (Life Technologies) and sequenced (Supplementary Fig. 12b).
KASP genotyping. For rapid genotyping of mutant zebraﬁsh harbouring the
c.629_630 deletion, a mutant allele-speciﬁc forward primer 50-GGGCACATAAT
AATCCTCCATGGT-30 , a wild-type allele-speciﬁc forward primer 50-GGCACAT
AATAATCCTCCATGGG-30 and a common reverse primer 50-CCCTGTATGTA
GGCCTTCGGGTT-30 were used (LGC Genomics). PCR ampliﬁcation was
performed using KASP Master mix (LGC Genomics) according to the manu-
facturer’s instructions. Fluorescence was read on a CFX96 Touch Real-Time PCR
Detection System (Bio-Rad) and the allelic discrimination plot generated using Bio-
Rad CFX Manager Software.
LC50 determination of MnCl2 in zebraﬁsh larvae. Exposure of wild-type and
slc39a14U801 embryos was commenced at 48 hpf and continued for 3 days.
Treatments with MnCl2 were performed in 6-well culture plates with 20 embryos
per well. MnCl2 was added directly to the ﬁsh water at the concentrations 50, 100,
250, 500, 750 and 1,500 mM. Dead larvae were counted at 5 dpf. LC50 concentra-
tions and relative median potency for wild-type and mutant zebraﬁsh larvae
were determined by Probit regression analysis using IBM SPSS Statistics package
version 21.
Locomotor zebraﬁsh behaviour assay. The behavioural assay was conducted as
described previously49. In brief, zebraﬁsh embryos and larvae were raised on a
14:10-h light/dark cycle. Single larvae were transferred to each well of a ﬂat-bottom,
clear polystyrene 96-well plate (Whatman) in ﬁsh water (650 ml) at 4 dpf. The
96-well plate was maintained at a constant temperature (28.5 C) and exposed to a
14:10-h white light/dark schedule with constant infrared illumination within a
custom-modiﬁed Zebrabox (Viewpoint Life Sciences). The locomotor behaviour of
zebraﬁsh larvae was tracked from 4 to 7 dpf using an automated video tracking
system (Viewpoint Life Sciences). Larval movement was recorded using Videotrack
Quantization mode. The Videotrack detection parameters were empirically deﬁned
for clean detection of larval movement with minimal noise. A custom-designed
Matlab code was used to extract the average activity data of each larva. Mn
exposure was achieved by adding MnCl2 (50 mM) directly to the ﬁsh water. Results
from genotypically presorted larvae were conﬁrmed by behavioural analysis of a
heterozygous in-cross with subsequent genotyping.
Cardiac injection of Na2CaEDTA. To assess the effect of Na2CaEDTA (disodium
calcium edetate also referred to as edetate calcium disodium, ethylene diamine
tetra-acetic acid disodium calcium salt) on Mn levels, slc39a14U801 larvae were
injected directly into the heart with 5 or 50 ng Na2CaEDTA after immobilization in
1.5% low-melting point agarose (in ﬁsh water with MS-222) using a pressure-
pulsed Picospritzer II (General Valve Corp). Injections were performed daily at 2, 3
and 4 dpf. Following injection, embryos were removed from the agarose and raised
in ﬁsh water supplemented with 50 mM MnCl2 from 2 dpf. Mn levels were
determined from pools of 10 larvae at 5 dpf by ICP-MS as described above.
Statistical analysis. Student’s two-tailed t-tests using the GraphPad Prism soft-
ware (version 5; GraphPad) were used to determine the statistical signiﬁcance of
differences between two groups. For comparisons with more than two conditions,
one-way ANOVAs with Tukey’s post hoc tests and two-way ANOVAs were
determined using IBM SPSS Statistics package version 21. Probit regression
analysis was performed using IBM SPSS Statistics package version 21.
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